Pfizer (PFE) R&D In Process (2021 - 2025)
Historic R&D In Process for Pfizer (PFE) over the last 7 years, with Q3 2025 value amounting to $1.4 billion.
- Pfizer's R&D In Process rose 1059230.77% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 145384.62%. This contributed to the annual value of $108.0 million for FY2024, which is 4432.99% down from last year.
- Pfizer's R&D In Process amounted to $1.4 billion in Q3 2025, which was up 1059230.77% from $2.0 million recorded in Q2 2025.
- Over the past 5 years, Pfizer's R&D In Process peaked at $1.4 billion during Q3 2025, and registered a low of $1.0 million during Q3 2022.
- For the 5-year period, Pfizer's R&D In Process averaged around $229.1 million, with its median value being $33.0 million (2023).
- Per our database at Business Quant, Pfizer's R&D In Process plummeted by 9954.34% in 2022 and then skyrocketed by 1059230.77% in 2025.
- Pfizer's R&D In Process (Quarter) stood at $706.0 million in 2021, then dropped by 25.78% to $524.0 million in 2022, then tumbled by 86.26% to $72.0 million in 2023, then tumbled by 81.94% to $13.0 million in 2024, then surged by 10592.31% to $1.4 billion in 2025.
- Its R&D In Process was $1.4 billion in Q3 2025, compared to $2.0 million in Q2 2025 and $9.0 million in Q1 2025.